Company News

Company News » Press Releases » Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

November 8, 2024

The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading scientists, industry experts, investors, and regulatory authorities at the GenScript Biotech Global Forum. This series of conferences aims to address key industrial trends in cell therapy and gene therapy.

In this November 20, GenScript Biotech Global Forum will take place in London during the Jefferies London Healthcare Conference.

For more information, please visit the forum website

Highlights from the GenScript Biotech Global Forum London 2024

Scheduled for November 20, 2024, during the Jefferies London Healthcare Conference, this year’s forum will explore the theme “Unlock the Full Potential of Cell and Gene Therapies.” This event aims to foster collaboration among industry leaders while tackling the challenges and opportunities in the CGT landscape.

Navigating Challenges: Insights into the Future of CGT and Multiple Cell Therapy Technologies in Development

In recent years, cell and gene therapy has become a key player in biopharmaceuticals, with a growing number of approvals annually. CAR-T therapies are the most advanced, while innovations have led to a wider range of cell therapies, including CAR-NK, CAR-M, and TIL, addressing various challenging diseases.

However, the diverse landscape of new therapies and technologies presents numerous challenges. The forum will feature keynote speeches from prominent figures in cell and gene therapy, including Dr. James M. Wilson, President and CEO of Gemma Biotherapeutics; Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT) and CEO of Kiji Therapeutics, and Tom Whitehead, co-founder of the Emily Whitehead Foundation will also give a speech to share the life-saving stories of CAR-T therapy.

In addition, industry leaders such as Pascal Touchon, Chairman of the Board of Atara Biotherapeutics, Biao Zheng, CEO of BRL Medicine Inc, Jason Foster, CEO of Ori Biotech, and Reagan Jarvis, CEO and Co-founder of Anocca AB will participate in the panel discussion exploring the future of the CGT industry. Also, Dr. Ying Huang, CEO of Legend Biotech, the world’s highest market value CAR-T company, will share the story of Legend’s success.

In-Depth Discussion on Gene Therapy and mRNA Vaccines

The development of gene therapy and mRNA vaccine technologies has been transformative, especially during the COVID-19 pandemic. These innovations also show great promise for rare diseases and genetic disorders. The forum will examine how advancements in gene editing are reshaping clinical applications. What innovations are emerging in the fields of gene therapy and mRNA vaccines? What challenges will arise as innovative technologies transition from R&D to clinical applications? Deividas Pazeraitis, Senior Scientist of AstraZeneca, Karim Benabdellah, Principal Investigator of GENYO, Maelle Quere, Scientist of Sanofi, Lumeng Ye, Director of Novel therapeutic materials in the R&D Department of GenScript Biotech, and Vincenzo Di Cerbo, Lead Technical Scientist of Cell and Gene Therapy Catapult will share their insight on emerging trends and challenges as these technologies transition from research to clinical applications.

Addressing CMC Challenges in Developing and Manufacturing CGT

Throughout the development and production of cell and gene therapies, CMC challenges abound. The quality of raw materials and the stability of supply chains directly impact the progress of early development. The complexity and consistency control of manufacturing processes from small-scale development to large-scale commercialization remain pressing issues, with process scaling and standardization requiring further optimization. Furthermore, ensuring product quality and safety in compliance with stringent regulatory requirements is a persistent challenge for successful market entry.

The forum will delve into market trends and future innovation opportunities through panel discussions. Industry leaders such as Dima Al-Hadithi, Director of Minaret Consulting Limited, Peter Jones, Director of Pengwin Consultancy, Ming Ewe, CEO of Smarter Biotech Solutions, Jim Faulkner, CEO of JDB BioConsulting, and Arindam Mitra, CMC Director at Leucid Bio, will come together to share strategies for overcoming current bottlenecks and driving innovation in CMC technologies, facilitating faster and safer market entry for CGT products.

Exploring the Investment Potential of CGT: A Future Outlook

Cell and gene therapies have shown exceptional effectiveness in treating a range of diseases, establishing them as a significant trend in modern healthcare. As CGT moves into a rapid commercialization phase, the sector presents numerous investment opportunities, along with associated risks and challenges.

What challenges do investment returns in the CGT industry face? Where are the key investment opportunities? How can insights attract funding for patient-benefiting solutions?

This forum will feature an investment session providing insights from an investor’s perspective, helping attendees understand the potential of CGT while aiming for long-term returns as therapies progress toward commercialization. Kelly Shi, Senior Vice President of Jefferies LLC, and Ping Shek, Managing Director of Stifel’s Global Healthcare Group will have a deep conversation about the investment trends in CGT.